ESC Congress 2023
LIBerate-HeFH: Lerodalcibep reduces LDL-C in HeFH
Lerodalcibep (LIB-003), a small recombinant fusion protein of a PCSK9-binding domain (adnectin) and human serum albumin (HSA), significantly reduces LDL-cholesterol (LDL-C) in patients with heterozygous familial hypercholesterolaemia (HeFH) on background stable lipid lowering therapy (LLT) and has shown promise in reducing LDL-C to ESC target…
read more »
ORION-8: Inclisiran shows efficacy and safety beyond six years
When added to statin therapy, twice-yearly* inclisiran consistently reduces low-density lipoprotein cholesterol (LDL-C) beyond six years, according to late-breaking data presented from the ORION-8 trial – an open label extension of the ORION-9, ORION-10, ORION-11 and ORION-3 studies in which patients were followed up for…
read more »
Phase 3 data show benefits of alirocumab in children with HeFH
Two- and four-weekly alirocumab significantly reduces LDL-cholesterol (LDL-C) and other pro-atherogenic lipid concentrations in paediatric patients with uncontrolled heterozygous familial hypercholesterolaemia (HeFH) on stable statin doses. This is the key takeaway from a Phase 3 randomised, double-blind, placebo-controlled international clinical trial (NCT03510884), presented by Professor…
read more »
REMAIN-1: Recaticimab significantly reduces LDL-C even with infrequent dosing
The investigational humanised PCSK9 monoclonal antibody, recaticimab, significantly reduces LDL-C in patients with non-familial hypercholesterolaemia (FH) and mixed hyperlipidaemia in dosing intervals up to 12 weeks. Results of the Phase 3 REMAIN-1 trial, presented by Dr Junbo Ge (Fudan University, Shanghai, China) showed significant changes…
read more »
